Prognose

Das durchschnittliche Kursziel der Analysten beträgt +6,80€(+32,81%). Der Median liegt bei +6,02€(+17,58%).

Kaufen	3
Halten	1
Verkaufen	2

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	6 / 18
Levermann-Strategie	-4 / 13

News

Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 Weeks
The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.» Mehr auf zacks.com
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
- Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases - STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8™ PGx pharmacogenomics testing service to offer tailored subpanels for indication-specific use cases in addition to full panel testing. The first subpanel under ADCL's new go-to-market strategy is for the pre-emptive testing of patients with genetic variants of the DPYD gene that correlate to potentially reduced or absent DPD enzyme activity necessary to metabolize fluoropyrimidines, specifically capecitabine (branded Xeloda) and fluorouracil (5-FU), two chemotherapy drugs that are widely used as part of the standard of care treatment for patients with certain cancers.» Mehr auf accessnewswire.com
23andMe bankruptcy: With America's DNA put on sale, market panic gets a new form of testing
The bankruptcy of consumer genetics testing company 23andMe last week led to widespread fears about the DNA of millions of Americans going on sale to the highest bidder. 23andMe has 15 million customers and with calls for users to delete their data, traffic to its website surged 526% on the day of its bankruptcy filing.» Mehr auf cnbc.com

Unternehmenszahlen

Im letzten Quartal hatte Ginkgo Bioworks einen Umsatz von 42,14 Mio€ und ein Nettoeinkommen von −103,34 Mio€

(EUR)	Dez. 2024	YOY
Umsatz	+42,14 Mio	34,03%
Bruttoeinkommen	+32,89 Mio	93,33%
Nettoeinkommen	−103,34 Mio	46,04%
EBITDA	−137,89 Mio	43,36%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+296,81 Mio€
Anzahl Aktien	58,03 Mio
52 Wochen-Hoch/Tief	+44,10€ - +4,87€
Dividenden	Nein
Beta	1,24
KGV (PE Ratio)	−0,52
KGWV (PEG Ratio)	−0,03
KBV (PB Ratio)	+0,40
KUV (PS Ratio)	+1,41

Unternehmensprofil

Ginkgo Bioworks Holdings, Inc. entwickelt zusammen mit seinen Tochtergesellschaften eine Plattform für die Zellprogrammierung. Die Plattform wird zur Programmierung von Zellen verwendet, um die biologische Herstellung von Produkten wie neuartigen Therapeutika, Lebensmittelzutaten und aus Erdöl gewonnenen Chemikalien zu ermöglichen. Das Unternehmen bedient verschiedene Endmärkte, darunter Spezialchemikalien, Landwirtschaft, Lebensmittel, Konsumgüter und Pharmazeutika. Ginkgo Bioworks hat eine Partnerschaft mit Selecta Biosciences, Inc. zur Entwicklung der ImmTOR-Technologieplattform. Ginkgo Bioworks Holdings, Inc. wurde im Jahr 2008 gegründet und hat seinen Hauptsitz in Boston, Massachusetts.